2018 ASCO Annual Meeting!
Session: Head and Neck Cancer
Type: Poster Session
Time: Saturday June 2, 1:15 PM to 4:45 PM
Location: Hall A
Using mobile and sensor technology to identify early dehydration risk in head and neck cancer patients undergoing radiation treatment: Impact on symptoms.
Head and Neck Cancer
2018 ASCO Annual Meeting
Poster Board Number:
Poster Session (Board #51)
J Clin Oncol 36, 2018 (suppl; abstr 6063)
Author(s): Susan K. Peterson, Adam S. Garden, Eileen H. Shinn, Sanjay Shete, Stephanie L. Martch, Maria Camero, George Baum, Emilia Farcas, Kai Lin, Frederic Raab, Viswanath Nandigam, Yan Yan, Renata Ferrarotto, Job Godino, Kevin Patrick, Beth Michelle Beadle; The University of Texas MD Anderson Cancer Center, Houston, TX; University of California, San Diego, La Jolla, CA; University of California, San Diego, San Diego, CA; Moores Cancer Center at UC San Diego Health, La Jolla, CA; University of California-San Diego, San Diego, CA
Background: Assessment and intervention with mobile and sensor technology may improve early detection and mitigation of treatment-related symptoms, impact quality of life (QOL), reduce complications, and lower health care costs. The CYCORE (CYberinfrastructure for COmparative effectiveness Research) system utilizes sensor and mobile technology to remotely assess daily weight, blood pressure (BP)/pulse, and patient-reported outcomes in head and neck cancer (HNC) patients undergoing radiation treatment (RT). Clinicians reviewed data daily to identify early risk of dehydration and support early intervention to improve symptom management. We compared longitudinal symptom data in patients randomized to use CYCORE during RT versus those randomized to usual care. Methods: Methods: HNC patients (n = 357) completed the 28-item MD Anderson Symptom Inventory (MDASI) at RT initiation (baseline), completion of RT (6-7 weeks post-baseline), and 6-8 weeks post-RT completion. Symptom severity and interference were rated on 0-10 scales; lower scores indicated better outcomes. Repeated measures ANOVA evaluated time point and group differences in MDASI scores. Results: Mean age was 60 years (range 25-86), 21% were female, 85% were White, and 54% completed college. Baseline MDASI mean scores were similar in patients randomized to CYCORE (n = 169) or usual care (n = 188). Mean scores on the severity of general and HNC-specific symptoms were lower in the CYCORE versus usual care group at completion of RT (2.92 vs. 3.4, p = .003; 4.21 vs 4.83, p = .009), and at 6-8 weeks post-RT completion (1.69 vs 1.96; p = .003; 1.78 vs. 2.11, p = .009). Mean scores on symptom interference in daily life were similar in both groups across time. Conclusions: HNC patients randomized to the CYCORE group during RT self-reported lower severity of general and HNC-specific symptoms compared to usual care. Sensor and mobile technology can enable monitoring of patients’ symptoms and related outcomes during critical periods of outpatient cancer treatment, can provide timely information to facilitate rapid clinical decision making about care, and may ultimately result in better QOL and health outcomes. Clinical trial information: NCT02253238
2. Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).